Applicant, as named in the Orange Book
Exelixis Inc
Next listed expiry: Cabometyx on 9 Jul 2033. 1 products with live protection, 0 without.
Products with listed protection
| Drug | Ingredient | Earliest generic entry | Basis |
|---|
| Cabometyx NDA 208692 · 3 strengths cabozantinib s-malate | cabozantinib s-malate | 9 Jul 2033 patent | patent |
Recent events
- Cabometyx · First generic approved · ANDA 213878, MsnApproved 14 Aug 2026·Detected 25 Oct 2026
- Cabometyx · Generic approved · ANDA 213878, MsnApproved 14 Aug 2026·Detected 25 Oct 2026
- Cabometyx · Generic approved · ANDA 217870, CiplaApproved 16 Oct 2026·Detected 25 Oct 2026